Genetic therapy may reduce tau protein responsible for Alzheimer's
Researchers have used gene therapy for the first time on Alzheimer's disease. It is helpful in safely reducing the tau protein responsible for the disease. The trial was led by consultant neurologist Dr Catherine Mummery (UCL Queen Square Institute of Neurology and the National Hospital for Neurology and Neurosurgery). Gene silencing in dementia and Alzheimer's disease was adopted during the trial. During this, the researchers used a drug, which is used to stop the RNA that produces the protein. It is helpful in reducing the gene coding for tau protein. It also reduces its production.
Dr Catherine said, we will need more research to understand to what extent the drug can slow the progression of the symptoms of the disease. It needs to be used on the elderly and a large group of people. The result of the research is encouraging that we can affect the tau protein with the help of gene silencing. This can also slow down or reverse the effects of Alzheimer's disease. The results of the first phase have been published in Nature Medicine. 46 people were included in this research. At present, there is no cure for the problems caused by the tau protein.
Comments
Post a Comment